Harmonized outcome measures for use in asthma patient registries and clinical practice

Abstract

Background: Asthma, a common chronic airway disorder, affects an estimated 25 million persons in the United States and 330 million persons worldwide. Although many asthma patient registries exist, the ability to link and compare data across registries is hindered by a lack of harmonization in the outcome measures collected by each registry. Objectives: The purpose of this project was to develop a minimum set of patient-and provider-relevant standardized outcome measures that could be collected in asthma patient registries and clinical practice. Methods: Asthma registries were identified through multiple sources and invited to join the workgroup and submit outcome measures. Additional measures were identified through literature searches and reviews of quality measures and consensus statements. Outcome measures were categorized by using the Agency for Healthcare Research and Quality's supported Outcome Measures Framework. A minimum set of broadly relevant measures was identified. Measure definitions were harmonized through in-person and virtual meetings. Results: Forty-six outcome measures, including those identified from 13 registries, were curated and harmonized into a minimum set of 21 measures in the Outcome Measures Framework categories of survival, clinical response, events of interest, patient-reported outcomes, resource utilization, and experience of care. The harmonized definitions build on existing consensus statements and are appropriate for adult and pediatric patients. Conclusions: The harmonized measures represent a minimum set of outcomes that are relevant in asthma research and clinical practice. Routine and consistent collection of these measures in registries and other systems would support creation of a national research infrastructure to efficiently address new questions and improve patient management and outcomes. (J

Common Data Elements to Facilitate Sharing and Re-use of Participant-Level Data: Assessment of Psychiatric Comorbidity Across Brain Disorders

“…To help achieve this level of collaboration and data interoperability, a set of common demographic and clinical outcome measures were identified and adopted across all of the aforementioned research programs. The adoption of common data elements (CDEs) within these studies reduces the variability of data collection, and ultimately supports the secondary use of Brain-CODE data by facilitating the pooling of participant-level data across datasets (1,(3)(4)(5)(6). The primary objective of the present study was to use the CDEs to assess psychiatric comorbidity across various neurological diseases.…”

“…These data must be sufficiently comparable to allow meaningful data integration, and in the absence of common demographic variables and outcome measures it is difficult to pool data from different initiatives (2). Establishment up front of a minimum set of unambiguously defined and standardized assessments across initiatives will facilitate data sharing and integration and enable meaningful cross-initiative analyses (3)(4)(5)(6).…”

Machine learning–driven identification of early-life air toxic combinations associated with childhood asthma outcomes

“…These outcomes included current need for daily asthma controller medication, lifetime emergency room visit for asthma, and lifetime overnight hospitalization for asthma (Figure 1). Asthma-related medication use, emergency room visits, and hospitalizations are frequently studied asthma outcomes that reflect asthma severity, control, and healthcare utilization (28)(29)(30). While some studies have reported associations between particular air toxics and these asthma subphenotypes (9,11,12), none addressed our goal to identify combinations of air toxics from a large national assessment of air toxics associated with these asthma outcomes.…”

Nanoparticle-based thymulin gene therapy therapeutically reverses key pathology of experimental allergic asthma

“…Asthma is one of the most common chronic pulmonary disorders, affecting more than 330 million people worldwide, but remains incurable despite decades of collective efforts to prevent, diagnose, and treat the disease in a timely manner (1). Current clinical guidelines recommend management of symptoms at best (2).…”